Biotechnology

Filter

Current filters:

None

Popular Filters

73 to 97 of 2296 results

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

02-08-2014

The US Food and Drug Administration on Friday approved Lumizyme (alglucosidase alfa) for treatment of…

BiotechnologyGenzymeLumizymeMyozymeRare diseasesRegulationSanofiUSA

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

UK aims to become world number one in DNA testing with new investment

UK aims to become world number one in DNA testing with new investment

01-08-2014

David Cameron, the UK Prime Minister, has announced a package of investment worth more than £300 million…

BiotechnologyDavid CameronGeneticsIlluminaMedical Research CouncilResearchUK

USA’s 340B Drug Discount Program “needs more oversight,” says BIO

USA’s 340B Drug Discount Program “needs more oversight,” says BIO

01-08-2014

The US Biotechnology Industry Organization’s (BIO) Laurel Todd shared concerns that the 340B program…

BiotechnologyFinancialHealthcareRegulationUSA

Harlan aims to provide expertise for biologics and biosimilars

31-07-2014

Switzerland-based Harlan Laboratories, a privately held provider of general and specialty toxicology…

BiosimilarsBiotechnologyContract research servicesHarlanRegulationResearchSwitzerlandToxicology services

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

Cellectis sells Swedish subsidiary to Japan’s Takara Bio

30-07-2014

France-based genome engineering specialist Cellectis says it has sold its Swedish subsidiary Cellectis…

BiotechnologyBusiness FinanceCellectisCellectis ABFranceMergers & AcquisitionsTakara Bio

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

30-07-2014

Amgen, the largest global independent biotech firm, reported a 23% leap in second-quarter 2014 profit…

AmgenBiotechnologyFinancialManagement

Targacept to drop TC-5214 development in overactive bladder

Targacept to drop TC-5214 development in overactive bladder

29-07-2014

US-based clinical-stage biopharma company Targacept plans to halt development of TC-5214 as a treatment…

AstraZenecaBiotechnologyGenito-urinaryResearchTargaceptTC-5214USA

Antiviral gel in condoms to kill HIV approved in Australia

Antiviral gel in condoms to kill HIV approved in Australia

28-07-2014

Australian biotech firm Starpharma says it has achieved a major milestone with the receipt of Conformity…

AnsellAnti-viralsAntibiotics and Infectious diseasesAustraliaBiotechnologyRegulationStarpharmaVivaGel

Taiho Pharma and Sumitomo Dainippon both invest in Remiges BioPharma Fund

25-07-2014

Japanese oncology-focussed drugmaker Taiho Pharmaceutical has said that it will be investing $30 million…

BiotechnologyDainippon Sumitomo PharmaFinancialJapanOncologyRemiges BioPharma FundTaiho Pharmaceutical

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

Celgene posts strong sales and earnings for 2nd-qtr

24-07-2014

US biotech firm Celgene reported net product sales of $1,845 million for the second quarter of 2014,…

BiotechnologyCelgene Corp.Financial

Gilead beats forecasts as Sovaldi sales soar

Gilead beats forecasts as Sovaldi sales soar

24-07-2014

US anti-virals specialist biotech firm Gilead Sciences has reported surging second-quarter 2014 sales…

Anti-viralsBiotechnologyBusiness FinanceBusiness FinanceChemistryFinancialFixed dose combinationGilead SciencesSovaldiTenofovir

US FDA approves Gilead’s Zydelig for three types of blood cancers

US FDA approves Gilead’s Zydelig for three types of blood cancers

24-07-2014

The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US…

BiotechnologyGilead SciencesidelalisibOncologyRegulationUSAZydelig

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

23-07-2014

Shares of US biotech firm Biogen Idec jumped 7.35% to $326 in pre-market trading today, as the company…

AlprolixBiogen IdecBiotechnologyElocateFinancialImmunologyPharmacologyTecfideraUSA

73 to 97 of 2296 results

Back to top